相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bone sarcomas in the immunotherapy era
Marie-Francoise Heymann et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
Clinical efficiency of epigenetic drugs therapy in bone malignancies
Filomena de Nigris et al.
BONE (2021)
Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours
Kenneth Hsu et al.
CANCER GENE THERAPY (2021)
B7-H3: An Attractive Target for Antibody-based Immunotherapy
Filippos Kontos et al.
CLINICAL CANCER RESEARCH (2021)
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
Julie Delyon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
FDAApproval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
Shaily Arora et al.
ONCOLOGIST (2021)
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
X. H. Wu et al.
ANNALS OF ONCOLOGY (2021)
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma
Rashmi Chugh et al.
CANCER (2021)
The management of metastatic GIST: current standard and investigational therapeutics
Ciara M. Kelly et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Livnat Jerby-Arnon et al.
NATURE MEDICINE (2021)
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease
Kamakoti P. Bhat et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Ewing's Sarcoma
Nicolo Riggi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma
Thao Q. Pham et al.
ONCOGENE (2021)
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis-Interest in making it a therapeutic target
Lucas Treps et al.
PHARMACOLOGY & THERAPEUTICS (2021)
The role of Denosumab in joint preservation for patients with giant cell tumour of bone
D. L. Perrin et al.
BONE & JOINT JOURNAL (2021)
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial
Hans-Joachim Schmoll et al.
JAMA ONCOLOGY (2021)
The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches
Anna Koumarianou et al.
CANCERS (2021)
Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma: a case report
Tuo Xing et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Eben I. Lichtman et al.
CLINICAL CANCER RESEARCH (2021)
The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
Nathan M. Kendsersky et al.
CLINICAL CANCER RESEARCH (2021)
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
Kentaro Ito et al.
EUROPEAN JOURNAL OF CANCER (2021)
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial
Jie Xu et al.
ONCOLOGIST (2021)
Rapid Detection and Signaling of DNA Damage by PARP-1
Nootan Pandey et al.
TRENDS IN BIOCHEMICAL SCIENCES (2021)
Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate
Kenji Iida et al.
CANCER DISCOVERY (2021)
Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
Yi Que et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Harsimrat Kaur Birdi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
Arthur Wingerter et al.
CANCERS (2021)
ASO Author Reflections: Patient-Derived Tumor Xenografts and Ex Vivo Models Mimic the Clinical Response of Locally Aggressive Tumors to Approved Drug Candidates
Fan Tang et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Patient-Derived Tumor Xenografts Plus Ex Vivo Models Enable Drug Validation for Tenosynovial Giant Cell Tumors
Fan Tang et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2021)
Gastrointestinal stromal tumours
Jean-Yves Blay et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
Maxwell Y. Lee et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Surgical resection of primary tumor in the extremities improves survival for metastatic soft-tissue sarcoma patients: a population-based study of the SEER database
M. Matsuoka et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma
Yoshiyuki Suehara et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2021)
Targeting tumor-associated macrophages to synergize tumor immunotherapy
Xiaonan Xiang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson et al.
NATURE REVIEWS CANCER (2021)
ETS transcription factors as emerging drug targets in cancer
Michael Hsing et al.
MEDICINAL RESEARCH REVIEWS (2020)
Novel therapeutic strategies for spinal osteosarcomas
M. Akhtar Anwar et al.
SEMINARS IN CANCER BIOLOGY (2020)
The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies
Btissame El Hassouni et al.
SEMINARS IN CANCER BIOLOGY (2020)
Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma
Guo Gord Zhu et al.
CLINICAL CANCER RESEARCH (2020)
GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma
Manish Charan et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Collective cancer invasion forms an integrin-dependent radioresistant niche
Anna Haeger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Different class IIa HDACs repressive complexes regulate specific epigenetic responses related to cell survival in leiomyosarcoma cells
Eros Di Giorgio et al.
NUCLEIC ACIDS RESEARCH (2020)
miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma
C. Molist et al.
CANCER LETTERS (2020)
Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma
Bongkum Choi et al.
CANCER LETTERS (2020)
Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications
Pichaya Thanindratarn et al.
CANCER TREATMENT REVIEWS (2020)
RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors
Jordan L. Kohlmeyer et al.
CLINICAL CANCER RESEARCH (2020)
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Emily Z. Keung et al.
CLINICAL CANCER RESEARCH (2020)
Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells
Tinka Haydn et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
Antoine Italiano et al.
LANCET ONCOLOGY (2020)
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
Roman Groisberg et al.
MOLECULAR CANCER THERAPEUTICS (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research
Corrie A. Painter et al.
NATURE MEDICINE (2020)
Targeting glutamine metabolism slows soft tissue sarcoma growth
Pearl Lee et al.
NATURE COMMUNICATIONS (2020)
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab A Phase 2 Clinical Trial
Ciara M. Kelly et al.
JAMA ONCOLOGY (2020)
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas A Nonrandomized Phase 1/2 Clinical Trial
Javier Martin-Broto et al.
JAMA ONCOLOGY (2020)
Lactate in Sarcoma Microenvironment: Much More than just a Waste Product
Maria Letizia Taddei et al.
CELLS (2020)
The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors
Riccardo Corbellari et al.
ANTI-CANCER DRUGS (2020)
Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor alpha-positive rhabdomyosarcoma
Wei Xiao et al.
CANCER (2020)
In vitro 4-1BB stimulation promotes expansion of CD8+tumor-infiltrating lymphocytes from various sarcoma subtypes
Morten Nielsen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma
Chuangzhong Deng et al.
CANCER SCIENCE (2020)
Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression
Samir Devalaraja et al.
CELL (2020)
Epigenetic Therapy for Epithelioid Sarcoma
Scott B. Rothbart et al.
CELL (2020)
Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis (vol 31, pg 174, 2020)
Peiwei Huangyang et al.
CELL METABOLISM (2020)
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing
Martee L. Hensley et al.
CLINICAL CANCER RESEARCH (2020)
Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Kenneth R. Gundle et al.
CLINICAL CANCER RESEARCH (2020)
The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures
Lingling Chen et al.
CLINICAL CANCER RESEARCH (2020)
Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Jennifer X. Ji et al.
CLINICAL CANCER RESEARCH (2020)
Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study
Jianliang Yang et al.
EUROPEAN JOURNAL OF CANCER (2020)
Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
Ece Canan Sayitoglu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
William D. Tap et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Lactate dehydrogenase supports lactate oxidation in mitochondria isolated from different mouse tissues
Adrian Young et al.
REDOX BIOLOGY (2020)
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups
Alessandro Gronchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
William D. Tap et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study.
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling
Gao Lixia et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Targeting epigenetics in sarcomas through EZH2 inhibition
Antoine Italiano
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
Antoine Italiano et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
TRK inhibition in soft tissue sarcomas: A comprehensive review
Tarek Assi et al.
SEMINARS IN ONCOLOGY (2020)
Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma
Aruna Marchetto et al.
NATURE COMMUNICATIONS (2020)
Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas
Javier Martin-Broto et al.
CLINICAL CANCER RESEARCH (2020)
Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade
Cesar Serrano et al.
CLINICAL CANCER RESEARCH (2020)
Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer
Peter E. Hall et al.
CLINICAL LUNG CANCER (2020)
Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation?
Azeem Tariq Malik et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2020)
Medical treatment of advanced malignant perivascular epithelioid cell tumors
Chiara Fabbroni et al.
CURRENT OPINION IN ONCOLOGY (2020)
A review of retroperitoneal liposarcoma genomics
Robert Tyler et al.
CANCER TREATMENT REVIEWS (2020)
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy
Martina Molgora et al.
CELL (2020)
Mitochondrial Metabolism as a Target for Cancer Therapy
Karthik Vasan et al.
CELL METABOLISM (2020)
Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma
Jeremy J. McGuire et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
Joost H. van den Berg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
Troels Holz Borch et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Dermatofibrosarcoma Protuberans: Update on the Diagnosis and Treatment
Xingpei Hao et al.
JOURNAL OF CLINICAL MEDICINE (2020)
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers
Hesham M. Amin et al.
CANCERS (2020)
Epithelioid Sarcoma-From Genetics to Clinical Practice
Anna M. Czarnecka et al.
CANCERS (2020)
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud et al.
CANCERS (2020)
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Bassel Nazha et al.
FRONTIERS IN ONCOLOGY (2020)
Oncolytic viruses for cancer immunotherapy
Otto Hemminki et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich et al.
LANCET ONCOLOGY (2020)
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial
Aaron R. Weiss et al.
LANCET ONCOLOGY (2020)
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Marie-Lisa Eich et al.
CANCER RESEARCH (2020)
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials
Mayanne M. T. Zhu et al.
CANCER TREATMENT REVIEWS (2020)
A Darker Side to Retinoic Acid Revealed by Sarcomas
Frances R. Balkwill
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Valeria Leuci et al.
CLINICAL CANCER RESEARCH (2020)
VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma
Alexander Englisch et al.
PEDIATRIC BLOOD & CANCER (2020)
Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review
Tarek Assi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Sarcoma treatment in the era of molecular medicine
Thomas G. P. Grunewald et al.
EMBO MOLECULAR MEDICINE (2020)
Ewing sarcoma protein promotes dissociation of poly(ADP-ribose) polymerase 1 from chromatin
Seon-gyeong Lee et al.
EMBO REPORTS (2020)
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy
Angela C. Hirbe et al.
EUROPEAN JOURNAL OF CANCER (2020)
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies
Sara M. Federico et al.
EUROPEAN JOURNAL OF CANCER (2020)
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Meenakshi Hegde et al.
NATURE COMMUNICATIONS (2020)
Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing
Amelie Boichard et al.
GENOME MEDICINE (2020)
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder et al.
LANCET ONCOLOGY (2020)
Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study
Chao Liu et al.
LANCET ONCOLOGY (2020)
EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma
Xianping Shi et al.
NUCLEIC ACIDS RESEARCH (2020)
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Tobias Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype
Abigail C. Cornwell et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming
Caitlyn B. Brashears et al.
CELL DEATH & DISEASE (2020)
RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis
Sara Sanchez-Molina et al.
SCIENCE ADVANCES (2020)
Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma by Targeting Autophagy and Apoptosis
Takashi Ando et al.
CANCERS (2020)
Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls
Hengyuan Li et al.
FRONTIERS IN ONCOLOGY (2020)
Natural killer cell-based immunotherapy for acute myeloid leukemia
Jing Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
Nadia Hindi et al.
CANCERS (2020)
Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials
Pierre-Yves Cren et al.
FRONTIERS IN ONCOLOGY (2020)
Therapeutic targeting of GPR20, selectively expressed in gastrointestinal stromal tumor (GIST), with DS-6157a, an antibody-drug conjugate (ADC)
Kenji Iida et al.
CANCER RESEARCH (2020)
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
Javier Martin-Broto et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
Bin Zhang et al.
MOLECULAR CANCER (2020)
A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma
Jason A. Somarelli et al.
CANCERS (2020)
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
Sean J. Judge et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
G. D. Demetri et al.
ANNALS OF ONCOLOGY (2020)
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients
Qiaoyun Tan et al.
THERANOSTICS (2020)
Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
A. Dufresne et al.
ONCOIMMUNOLOGY (2020)
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE' (vol 28, pg 3000, 2017)
P. Schoffski et al.
ANNALS OF ONCOLOGY (2019)
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
Cornelia Hutmacher et al.
ADVANCED DRUG DELIVERY REVIEWS (2019)
Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04)
Ulrich Ronellenfitsch et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy
Wei Yu et al.
BIOMATERIALS (2019)
Neurological toxicities associated with chimeric antigen receptor T-cell therapy
Daniel B. Rubin et al.
BRAIN (2019)
Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
Zhengxiao Ouyang et al.
CELL COMMUNICATION AND SIGNALING (2019)
SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma
Ilka Isfort et al.
CLINICAL CANCER RESEARCH (2019)
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma
Henry G. Smith et al.
CLINICAL CANCER RESEARCH (2019)
Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner
Matt L. Harlow et al.
CLINICAL CANCER RESEARCH (2019)
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial
Sandro Pasquali et al.
EUROPEAN JOURNAL OF CANCER (2019)
Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma
Gangyang Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor
Gerardo A. Vitiello et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion
Sabine Heitzeneder et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells
Sareetha Kailayangiri et al.
MOLECULAR THERAPY (2019)
Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Dario Neri
CANCER IMMUNOLOGY RESEARCH (2019)
Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy
Megan M. Tu et al.
SCIENCE ADVANCES (2019)
Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy
Sebastian Klein et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells
J. Fellenberg et al.
CANCER LETTERS (2019)
Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma
Elizabeth R. Butch et al.
CANCER RESEARCH (2019)
Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy
Jelena Levi et al.
CANCER RESEARCH (2019)
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors
Bethany C. Prudner et al.
CLINICAL CANCER RESEARCH (2019)
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials
Sheri L. Spunt et al.
EUROPEAN JOURNAL OF CANCER (2019)
Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements
Jason C. Chang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target
Francois Bertucci et al.
MOLECULAR ONCOLOGY (2019)
Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells
David H. M. Steffin et al.
MOLECULAR THERAPY (2019)
p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma
Arthur W. Currier et al.
SCIENTIFIC REPORTS (2019)
Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
Vito Longo et al.
CANCERS (2019)
MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma
Anthony P. Conley et al.
CANCERS (2019)
Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review
Milea J. M. Timbergen et al.
FRONTIERS IN ONCOLOGY (2019)
Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations
Yoshiyuki Suehara et al.
CLINICAL CANCER RESEARCH (2019)
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano et al.
CLINICAL CANCER RESEARCH (2019)
MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
Milind D. Chalishazar et al.
CLINICAL CANCER RESEARCH (2019)
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Neeta Somaiah et al.
CLINICAL CANCER RESEARCH (2019)
Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease
M. E. Weidema et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Targeting fusion proteins: a double edge sword?
Oscar M. Tirado
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Breelyn A. Wilky
IMMUNOLOGICAL REVIEWS (2019)
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E. Davis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Emerging trends in immunotherapy for pediatric sarcomas
Kyle A. Dyson et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
Yu Jin Kim et al.
LABORATORY INVESTIGATION (2019)
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap et al.
LANCET (2019)
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
Ian Judson et al.
LANCET ONCOLOGY (2019)
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
Maud Toulmonde et al.
LANCET ONCOLOGY (2019)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky et al.
LANCET ONCOLOGY (2019)
Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
Xiaojie Yu et al.
MABS (2019)
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
Amanda R. Dancsok et al.
MODERN PATHOLOGY (2019)
TP53 in bone and soft tissue sarcomas
Elizabeth Thoenen et al.
PHARMACOLOGY & THERAPEUTICS (2019)
T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human
Qian Sun et al.
CELL DEATH & DISEASE (2019)
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
Stefan Groesche et al.
NATURE COMMUNICATIONS (2019)
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
Shihong Zhang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft
Silvia Stacchiotti et al.
CANCERS (2019)
MDM2 Derived from Dedifferentiated Liposarcoma Extracellular Vesicles Induces MMP2 Production from Preadipocytes
Lucia Casadei et al.
CANCER RESEARCH (2019)
Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas
Roberta Frapolli et al.
CLINICAL CANCER RESEARCH (2019)
Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study
A. Le Cesne et al.
EUROPEAN JOURNAL OF CANCER (2019)
Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group
Leo Mascarenhas et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma
Makoto Nakagawa et al.
ONCOGENE (2019)
Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold
Anna Maria Gasparri et al.
SMALL (2019)
Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy
Maria Vela et al.
FRONTIERS IN IMMUNOLOGY (2019)
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
Vaia Florou et al.
Journal for ImmunoTherapy of Cancer (2019)
Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
Jared M. Newton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis
Amal M. El-Naggar et al.
EMBO REPORTS (2019)
Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity
Ondrej Uher et al.
SEMINARS IN ONCOLOGY (2019)
An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)
C. R. Mehta et al.
ANNALS OF ONCOLOGY (2019)
A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis
Johann Sellner et al.
AUTOIMMUNITY REVIEWS (2019)
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
Indu Ramachandran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor
Jocelyn Joseph et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Theodore S. Nowicki et al.
CLINICAL CANCER RESEARCH (2019)
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Robbie G. Majzner et al.
CLINICAL CANCER RESEARCH (2019)
ImmunologicCorrelates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy
Mrinal M. Gounder et al.
CLINICAL CANCER RESEARCH (2019)
Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma
Pilar Puerto-Camacho et al.
CLINICAL CANCER RESEARCH (2019)
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Lillian M. Guenther et al.
CLINICAL CANCER RESEARCH (2019)
Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy
Chihab Klose et al.
BMC CANCER (2019)
Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
Nora Sundahl et al.
EUROPEAN UROLOGY (2019)
Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies
Maximilian M. L. Knott et al.
CANCER AND METASTASIS REVIEWS (2019)
TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening
Catherine M. Albert et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud et al.
LANCET ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Small-molecule targeting of brachyury transcription factor addiction in chordoma
Tanaz Sharifnia et al.
NATURE MEDICINE (2019)
Denosumab for giant cell tumour of bone: success and limitations
John H. Healey
LANCET ONCOLOGY (2019)
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study
Sant Chawla et al.
LANCET ONCOLOGY (2019)
Adoptive cellular therapies: the current landscape
Maartje W. Rohaan et al.
VIRCHOWS ARCHIV (2019)
Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma A Review
Luca Paoluzzi et al.
JAMA ONCOLOGY (2019)
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
Sanne Venneker et al.
CANCERS (2019)
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
Manuel Piechutta et al.
ESMO OPEN (2019)
ABI-009 (nab-Sirolimus) improves tumor accumulation and antitumor activity over oral mTOR inhibitors
Shihe Hou et al.
CANCER RESEARCH (2019)
LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival
Yi Que et al.
CANCER BIOLOGY & MEDICINE (2019)
Pazopanib in advanced soft tissue sarcomas
Alex T. J. Lee et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
David T. W. Jones et al.
NATURE REVIEWS CANCER (2019)
F-18-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma
James C. Davis et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A. McKenzie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas
Michael J. Nathenson et al.
ONCOLOGIST (2018)
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A. McKenzie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy
Emily Z. Keung et al.
ONCOIMMUNOLOGY (2018)
ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus
Nissreen Mohammad et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Long-Term Outcome After Surgery for a Localized Retroperitoneal Soft Tissue Sarcoma in Elderly Patients: Results from a Retrospective, Single-Center Study
I. Sourrouille et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma
Ana Banito et al.
CANCER CELL (2018)
Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma
Binghao Li et al.
CANCER RESEARCH (2018)
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates
James W. Purcell et al.
CANCER RESEARCH (2018)
Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Caterina Mancarella et al.
CLINICAL CANCER RESEARCH (2018)
Interventional radiology: Role in the treatment of sarcomas
Thierry de Baere et al.
EUROPEAN JOURNAL OF CANCER (2018)
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model
Hans D. Menssen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Emerging Targeted and Immune-Based Therapies in Sarcoma
Seth M. Pollack et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives
Brigitte C. Widemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Locally Aggressive Connective Tissue Tumors
Mrinal M. Gounder et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment
Jalal A. Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition
Nisha Rao et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
A start towards immunotherapy in sarcomas?
Peter Hohenberger
LANCET ONCOLOGY (2018)
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D'Angelo et al.
LANCET ONCOLOGY (2018)
Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
Kathleen I. Pishas et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours
Armelle Dufresne et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Newer therapeutic strategies for soft-tissue sarcomas
Kevin Bourcier et al.
PHARMACOLOGY & THERAPEUTICS (2018)
PAX3-FOXO1: Zooming in on an undruggable target
Marco Wachtel et al.
SEMINARS IN CANCER BIOLOGY (2018)
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma
Sandra P. D'Angelo et al.
CANCER DISCOVERY (2018)
Does a less intensive surveillance protocol affect the survival of patients after treatment of a sarcoma of the limb? UPDATED RESULTS OF THE RANDOMIZED TOSS STUDY
A. Puri et al.
BONE & JOINT JOURNAL (2018)
Tumor-derived CSF-1 induces the NKG2D ligand RAE-1δ on tumor-infiltrating macrophages
Thornton W. Thompson et al.
ELIFE (2018)
Histology of ancient soft tissue tumors: A review
Gino Fornaciari
INTERNATIONAL JOURNAL OF PALEOPATHOLOGY (2018)
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
Patrick Schoffski et al.
LANCET RESPIRATORY MEDICINE (2018)
Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma
Kirtesh R. Patel et al.
ONCOIMMUNOLOGY (2018)
Ewing sarcoma
Thomas G. P. Gruenewald et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas A Phase 2 Clinical Trial
Maud Toulmonde et al.
JAMA ONCOLOGY (2018)
Translational insights into gastrointestinal stromal tumor and current clinical advances
M. L. Hemming et al.
ANNALS OF ONCOLOGY (2018)
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
Emily Z. Keung et al.
BMC CANCER (2018)
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
Steven G. DuBois et al.
CANCER (2018)
The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one
M. Nuti et al.
CANCER TREATMENT REVIEWS (2018)
Genome-scale CRI SPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
Bjorn Stolte et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Guoshuang Shen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
Sietse J. Luk et al.
ONCOIMMUNOLOGY (2018)
Response to PD1 inhibition in conventions chondrosarcoma
Michael J. Wagner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
David A. Mahvi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response
Kripa Guram et al.
FRONTIERS IN ONCOLOGY (2018)
Tenascin-C Promotes Tumor Cell Migration and Metastasis through Integrin α9β1-Mediated YAP Inhibition
Zhen Sun et al.
CANCER RESEARCH (2018)
The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma
F. Bertucci et al.
ANNALS OF ONCOLOGY (2018)
Gastrointestinal Stromal Tumors: The GIST of Precision Medicine
Lin Mei et al.
TRENDS IN CANCER (2018)
The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
Emanuela Palmerini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma
Theodore S. Nowicki et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G
Sareetha Kailayangiri et al.
ONCOIMMUNOLOGY (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study
Yael P. Mosse et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Audrey Laroche-Clary et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment
Marcella Tazzari et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon et al.
LANCET ONCOLOGY (2017)
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Alessandro Gronchi et al.
LANCET ONCOLOGY (2017)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
Ymera Pignochino et al.
MOLECULAR CANCER (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells
Tinka Haydn et al.
CELL DEATH & DISEASE (2017)
A comprehensive review of lysine-specific demethylase 1 and its roles in cancer
Amir Hosseini et al.
EPIGENOMICS (2017)
Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma
Alexander A. Tong et al.
ONCOIMMUNOLOGY (2017)
Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial
Robert J. Canter et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report
Simran Sindhu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma
Christine M. Heske et al.
CLINICAL CANCER RESEARCH (2017)
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen
Amy Barone et al.
CLINICAL CANCER RESEARCH (2017)
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'
P. Schoffski et al.
ANNALS OF ONCOLOGY (2017)
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)
J. Martin-Broto et al.
ANNALS OF ONCOLOGY (2017)
Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition
Prashanth J. Prabakaran et al.
CLINICAL CANCER RESEARCH (2017)
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma
Marcel Trautmann et al.
CLINICAL CANCER RESEARCH (2017)
Comprehensive Analysis of Hypermutation in Human Cancer
Brittany B. Campbell et al.
CELL (2017)
Emerging Opportunities for Target Discovery in Rare Cancers
Tanaz Sharifnia et al.
CELL CHEMICAL BIOLOGY (2017)
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Lucia Fernandez et al.
CLINICAL CANCER RESEARCH (2017)
Therapeutic applications of histone deacetylase inhibitors in sarcoma
Fan Tang et al.
CANCER TREATMENT REVIEWS (2017)
Expression and Therapeutic Potential of SOX9 in Chordoma
Hua Chen et al.
CLINICAL CANCER RESEARCH (2017)
Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study
Eytan Ben-Ami et al.
CANCER (2017)
Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Chiara Ratti et al.
CLINICAL CANCER RESEARCH (2017)
T-Cell Infiltration and Clonality Correlate With Programmed Cell Death Protein 1 and Programmed Death-Ligand 1 Expression in Patients With Soft Tissue Sarcomas
Seth M. Pollack et al.
CANCER (2017)
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Yulong Gao et al.
NATURE IMMUNOLOGY (2017)
Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin
Jayasree S. Nair et al.
CLINICAL CANCER RESEARCH (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative
Tine Cuppens et al.
CLINICAL CANCER RESEARCH (2017)
A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells
Sherly Mardiana et al.
CANCER RESEARCH (2017)
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
Kate Lynn J. Bill et al.
CLINICAL CANCER RESEARCH (2016)
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Melinda S. Merchant et al.
CLINICAL CANCER RESEARCH (2016)
Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)
Silvia Stacchiotti et al.
CLINICAL CANCER RESEARCH (2016)
Melatonin suppression of aerobic glycolysis (Warburg effect), survival signalling and metastasis in human leiomyosarcoma
Lulu Mao et al.
JOURNAL OF PINEAL RESEARCH (2016)
Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib
Victor Wong et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib
Victor Wong et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Recurrent CIC Gene Abnormalities in Angiosarcomas A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations
Shih-Chiang Huang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcomaaEuro
M. A. Dickson et al.
ANNALS OF ONCOLOGY (2016)
Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2016)
TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
Laurie Menger et al.
CANCER RESEARCH (2016)
CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling
Haibo Sun et al.
CANCER RESEARCH (2016)
Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group
Kieuhoa T. Vo et al.
CLINICAL CANCER RESEARCH (2016)
mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo
James J. Morrow et al.
CLINICAL CANCER RESEARCH (2016)
Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor
Christy L. Osgood et al.
CLINICAL CANCER RESEARCH (2016)
Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
Melinda S. Merchant et al.
CLINICAL CANCER RESEARCH (2016)
The role of regional chemotherapy in the management of extremity soft tissue malignancies
H. G. Smith et al.
EJSO (2016)
Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway
Annemiek M. van Maldegem et al.
EUROPEAN JOURNAL OF CANCER (2016)
Biology and management of clear cell sarcoma: state of the art and future perspectives
Jasmien Cornillie et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma
Maria Bohm et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
Mrinal M. Gounder et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
Georgia J. B. McCaughan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor
Joo O. Hyun et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
Salah-Eddine Lamhamedi-Cherradi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Antitumor Response of VEGFR2-and VEGFR3-Amplified Angiosarcoma to Pazopanib
Vinod Ravi et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study
Antoine Italiano et al.
LANCET ONCOLOGY (2016)
Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
Maurizio Ghisoli et al.
MOLECULAR THERAPY (2016)
Role of the EZH2 histone methyltransferase as a therapeutic target in cancer
Antoine Italiano
PHARMACOLOGY & THERAPEUTICS (2016)
High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility
Samantha G. Pattenden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma
Michael P. Phelps et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Integrated genetic and pharmacologic interrogation of rare cancers
Andrew L. Hong et al.
NATURE COMMUNICATIONS (2016)
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Joonil Jung et al.
NATURE COMMUNICATIONS (2016)
Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth
Michael S. Nakazawa et al.
NATURE COMMUNICATIONS (2016)
Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma
Tomoyo Okada et al.
CANCER DISCOVERY (2016)
Development and clinical application of an integrative genomic approach to personalized cancer therapy
Andrew V. Uzilov et al.
GENOME MEDICINE (2016)
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
Salah-Eddine Lamhamedi-Cherradi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Adrienne H. Long et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
Mark A. Dickson et al.
JAMA ONCOLOGY (2016)
Inhibiting cancer cell hallmark features through nuclear export inhibition
Qingxiang Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)
E. Bompas et al.
ANNALS OF ONCOLOGY (2015)
Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
Adrian von Witzleben et al.
CANCER RESEARCH (2015)
Targeted therapies for advanced Ewing sarcoma family of tumors
Yunyun Jiang et al.
CANCER TREATMENT REVIEWS (2015)
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment
Todd VanArsdale et al.
CLINICAL CANCER RESEARCH (2015)
Imatinib in advanced chordoma: A retrospective case series analysis
Nadia Hindi et al.
EUROPEAN JOURNAL OF CANCER (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
FDA Approves New Agent for Multiple Myeloma
Marilyn P. Fenichel
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study
Akira Kawai et al.
LANCET ONCOLOGY (2015)
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial
Axel Le Cesne et al.
LANCET ONCOLOGY (2015)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Giovanni Grignani et al.
LANCET ONCOLOGY (2015)
Building a global consensus approach to chordoma: a position paper from the medical and patient community
Silvia Stacchiotti et al.
LANCET ONCOLOGY (2015)
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
Patricia Pautier et al.
LANCET ONCOLOGY (2015)
Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas
Esma Saada-Bouzid et al.
MODERN PATHOLOGY (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
W. D. Tap et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele et al.
CANCER DISCOVERY (2015)
FDA Approves New Agent for Multiple Myeloma
Marilyn P. Fenichel
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
Edwin Choy et al.
BMC CANCER (2014)
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
M. D'Incalci et al.
BRITISH JOURNAL OF CANCER (2014)
Combined Anti-CD40 and Anti-IL-23 Monoclonal Antibody Therapy Effectively Suppresses Tumor Growth and Metastases
Bianca von Scheidt et al.
CANCER RESEARCH (2014)
Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
Savita Sankar et al.
CLINICAL CANCER RESEARCH (2014)
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
Sam Behjati et al.
NATURE GENETICS (2013)
Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma
S. Sankar et al.
ONCOGENE (2013)
Phase II Study of Ganitumab, a Fully Human Anti-Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors
William D. Tap et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II Study of Imatinib in Advanced Chordoma
Silvia Stacchiotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models
Pedro J. Beltran et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Regulation of cancer cell metabolism
Rob A. Cairns et al.
NATURE REVIEWS CANCER (2011)
Advances in sarcoma genomics and new therapeutic targets
Barry S. Taylor et al.
NATURE REVIEWS CANCER (2011)
Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma
Ian J. Davis et al.
CANCER RESEARCH (2010)
Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo
Sarah C. Mutka et al.
CANCER RESEARCH (2009)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Prognostic value of CD40 in adult soft tissue sarcomas
A Ottaiano et al.
CLINICAL CANCER RESEARCH (2004)
分享论文
